This study is recruiting. It focuses on depression and currently lists participation information in the United States.
This study is comparing WellPATH-PREVENT with Attention Control Usual Care (R33) for people with Suicide, Attempted, Suicidal Ideation, or Depression. Participants receive WellPATH-PREVENT or Attention Control Usual Care (R33) and complete study visits and assessments. Some participants may receive Attention Control Usual Care (R33) instead of the study treatment, and direct benefit is not guaranteed.
The official record suggests in-person participation through a hospital, with sites including New York Presbyterian Hospital/Weill Cornell Medicine and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine in White Plains. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and meeting the main study requirements, while common reasons not to take part include other factors that could make participation unsuitable and other clinical factors that could make participation unreliable or unsafe. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may help test a support approach in real life.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with usual care. Direct benefit is not guaranteed.
This study is sponsored by Weill Medical College of Cornell University. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.
This study may involve digital app or tool, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.